We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 17, 2022

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes

JNCI Cancer Spectrum


Additional Info

Disclosure statements are available on the authors' profiles:

JNCI Cancer Spectrum
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
JNCI Cancer Spectr 2022 Jul 01;6(4)pkac043, ND James, FC Ingleby, NW Clarke, CL Amos, G Attard, CD Brawley, S Chowdhury, W Cross, DP Dearnaley, DC Gilbert, S Gillessen, RJ Jones, RE Langley, A Macnair, ZI Malik, MD Mason, DJ Matheson, R Millman, CC Parker, HL Rush, JM Russell, C Au, AWS Ritchie, RP Mestre, I Ahmed, AJ Birtle, SJ Brock, P Das, VA Ford, EK Gray, RJ Hughes, CB Manetta, DB McLaren, AD Nikapota, JM O'Sullivan, C Perna, C Peedell, AS Protheroe, S Sundar, JS Tanguay, SP Tolan, J Wagstaff, JB Wallace, JP Wylie, A Zarkar, MKB Parmar, MR Sydes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading